Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction.

Mega JL, Morrow DA, Ostör E, Dorobantu M, Qin J, Antman EM, Braunwald E.

Circulation. 2007 Jun 5;115(22):2822-8. Epub 2007 May 21.

3.

Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis.

Giraldez RR, Wiviott SD, Nicolau JC, Mohanavelu S, Morrow DA, Antman EM, Giugliano RP.

Drugs. 2009 Jul 30;69(11):1433-43. doi: 10.2165/00003495-200969110-00003.

PMID:
19634922
4.

Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.

Sabatine MS, Morrow DA, Dalby A, Pfisterer M, Duris T, Lopez-Sendon J, Murphy SA, Gao R, Antman EM, Braunwald E; ExTRACT-TIMI 25 Investigators..

J Am Coll Cardiol. 2007 Jun 12;49(23):2256-63. Epub 2007 May 25.

5.
6.

Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis.

Giraldez RR, Nicolau JC, Corbalan R, Gurfinkel EP, Juarez U, Lopez-Sendon J, Parkhomenko A, Molhoek P, Mohanavelu S, Morrow DA, Antman EM.

Eur Heart J. 2007 Jul;28(13):1566-73. Epub 2007 Jun 11.

PMID:
17562672
7.

Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.

Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, López-Sendón JL, Guneri S, Jiang F, White HD, Fox KA, Braunwald E; ExTRACT-TIMI 25 Investigators..

N Engl J Med. 2006 Apr 6;354(14):1477-88. Epub 2006 Mar 14.

8.

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.

Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H; SYNERGY Trial Investigators..

JAMA. 2004 Jul 7;292(1):45-54.

PMID:
15238590
9.
11.

Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.

Gibson CM, Murphy SA, Montalescot G, Morrow DA, Ardissino D, Cohen M, Gulba DC, Kracoff OH, Lewis BS, Roguin N, Antman EM, Braunwald E; ExTRACT-TIMI 25 Investigators..

J Am Coll Cardiol. 2007 Jun 12;49(23):2238-46. Epub 2007 May 25.

12.

The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.

Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman A, Krzeminska-Pakula M, Danchin N, White HD, Santopinto J, Bigonzi F, Hecquet C, Vittori L; TETAMI Investigators..

J Am Coll Cardiol. 2003 Oct 15;42(8):1348-56.

13.

Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.

Weaver WD, White HD, Wilcox RG, Aylward PE, Morris D, Guerci A, Ohman EM, Barbash GI, Betriu A, Sadowski Z, Topol EJ, Califf RM.

JAMA. 1996 Mar 13;275(10):777-82.

PMID:
8598594
14.

Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II).

Ross AM, Molhoek P, Lundergan C, Knudtson M, Draoui Y, Regalado L, Le Louer V, Bigonzi F, Schwartz W, de Jong E, Coyne K; HART II Investigators..

Circulation. 2001 Aug 7;104(6):648-52.

15.
16.

TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction.

Ruff CT, Wiviott SD, Morrow DA, Mohanavelu S, Murphy SA, Antman EM, Braunwald E; ExTRACT-TIMI 25 Investigators..

Am J Med. 2007 Nov;120(11):993-8.

PMID:
17976428
17.

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.

Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM; 'A to Z' Investigators..

JAMA. 2004 Jul 7;292(1):55-64. Erratum in: JAMA. 2004 Sep 8;292(10):1178. Dosage error in article text.

PMID:
15238591
18.

Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events).

Montalescot G, Ellis SG, de Belder MA, Janssens L, Katz O, Pluta W, Ecollan P, Tendera M, van Boven AJ, Widimsky P, Andersen HR, Betriu A, Armstrong P, Brodie BR, Herrmann HC, Neumann FJ, Effron MB, Lu J, Barnathan ES, Topol EJ; Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events Investigators..

JACC Cardiovasc Interv. 2010 Feb;3(2):203-12. doi: 10.1016/j.jcin.2009.11.012.

20.

Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.

Cohen M, Théroux P, Borzak S, Frey MJ, White HD, Van Mieghem W, Senatore F, Lis J, Mukherjee R, Harris K, Bigonzi F; ACUTE II Investigators..

Am Heart J. 2002 Sep;144(3):470-7.

PMID:
12228784

Supplemental Content

Support Center